The Role of Neoadjuvant Chemo and Biomarker-Driven Maintenance in Gyn Cancer

In 2026, the landscape of gynecologic oncology is defined by a significant transition from broad-spectrum treatments to a precision-based model, where therapeutic decisions are increasingly dictated by a tumor's molecular fingerprint. Central to this evolution is the use of personalized maintenance therapies—interventions designed to delay recurrence and improve long-term survival by targeting specific genetic vulnerabilities.

In part 3 of Targeted Oncology’s interview with Erin Crane, MD, MPH, she weighs the decision of treating patients with neoadjuvant chemotherapy vs immediate referral for primary surgery.

Watch part 1 and part 2 of the interviews here.